CN Patent

CN102858321A — 用于局部使用1-氨基-烷基环己烷衍生物的凝胶制剂

Assigned to Merz Pharma GmbH and Co KGaA · Expires 2013-01-02 · 13y expired

What this patent protects

本发明提供了用于对需要其的患者的皮肤局部应用的用于治疗或预防炎性皮肤病例如，接触传染性脓疱病、痤疮、红斑痤疮、湿疹、特应性皮炎、接触性皮炎、脂溢性皮炎、银屑病和油性皮肤的药物组合物，其包含奈拉美生或其药学可接受的盐和至少一种胶凝剂。该至少一种胶凝剂包含具有中性聚合物骨架和带正电荷的聚合物骨架的聚合物。

USPTO Abstract

本发明提供了用于对需要其的患者的皮肤局部应用的用于治疗或预防炎性皮肤病例如，接触传染性脓疱病、痤疮、红斑痤疮、湿疹、特应性皮炎、接触性皮炎、脂溢性皮炎、银屑病和油性皮肤的药物组合物，其包含奈拉美生或其药学可接受的盐和至少一种胶凝剂。该至少一种胶凝剂包含具有中性聚合物骨架和带正电荷的聚合物骨架的聚合物。

Drugs covered by this patent

naftifine-hydrochloride (NAFTIFINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN102858321A
Jurisdiction: CN
Classification: —
Expires: 2013-01-02
Drug substance claim: No
Drug product claim: No
Assignee: Merz Pharma GmbH and Co KGaA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.